Humacyte

Humacyte Debt Growth

The Year-over-Year Debt Growth of Humacyte (HUMA) as of Nov 21, 2026 is 292.13 %. In the previous year, Year-over-Year Debt Growth was -71.22 % — a change of -510.20% (higher).

Debt Growth

292.13 %

YoY

-510.20%

Last updated:

Year-over-Year Debt Growth of Humacyte is 2025 292.13 % . Year-over-Year Debt Growth of Humacyte was 2024 -71.22 % . It decreases by -510.20% higher compared to the previous year.

The Humacyte Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2020
0.50 USD
Jan 1, 2021
77.33 USD
Jan 1, 2022
-2.17 USD
Jan 1, 2023
14.75 USD
Jan 1, 2024
-71.22 USD
Jan 1, 2025
292.13 USD
The Humacyte Debt Growth history
YEARDebt GrowthYoY
292.13 %-510.20%
-71.22 %-582.68%
14.75 %-779.05%
-2.17 %-102.81%
77.33 %+15,428.97%
0.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humacyte Stock analysis

What does Humacyte do? Humacyte, Inc. develops and manufactures off-the-shelf, universally implantable bioengineered human tissues and advanced tissue constructs. The company focuses on human acellular vessels (HAVs) targeting vascular repair, reconstruction, and replacement markets, including vascular trauma, AV access for hemodialysis, peripheral arterial disease, and coronary artery bypass grafting. HAVs are also being developed for pediatric heart surgery and cellular therapies like pancreatic islet cell transplantation for Type 1 diabetes. The company's technology platform uses primary human aortic vascular cells to mimic human physiology. Humacyte's products are sold to healthcare providers and medical institutions for surgical procedures requiring tissue replacement. The vascular repair and hemodialysis markets represent key segments where HAVs address unmet clinical needs. Pediatric heart surgery applications target specialized medical centers, while cellular therapy delivery focuses on diabetes treatment centers. The company's novel manufacturing paradigm enables universal implantability without immune rejection. The firm's revenue streams derive from the sale of HAVs for vascular procedures and their expansion into pediatric and cellular therapy applications. Market segments include vascular surgery, nephrology for hemodialysis access, and endocrinology for diabetes treatment. HAVs are positioned as a solution for patients requiring tissue grafts with reduced risk of rejection compared to traditional methods. Humacyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humacyte stock

Year-over-Year Debt Growth of Humacyte is 292.13 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Humacyte since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Humacyte historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Humacyte

All Key Metrics — Humacyte